Vicapsys Life Sciences, Inc. (VICP)
USD 1.77
(39.37%)
USD 1.77
(39.37%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.04 Million USD | -6.31% |
| 2022 | -984.79 Thousand USD | -192.33% |
| 2021 | -336.87 Thousand USD | 56.01% |
| 2020 | -765.84 Thousand USD | 25.93% |
| 2019 | -1.03 Million USD | 19.51% |
| 2018 | -1.28 Million USD | 60.28% |
| 2017 | -3.23 Million USD | 0.0% |
| 2009 | -1.35 Million USD | 42.63% |
| 2008 | -2.35 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q4 | -527.2 Thousand USD | -200.53% |
| 2023 Q1 | -211.27 Thousand USD | 57.11% |
| 2023 Q3 | -175.42 Thousand USD | -29.28% |
| 2023 Q2 | -135.69 Thousand USD | 35.77% |
| 2022 FY | -984.79 Thousand USD | -192.33% |
| 2022 Q2 | -180.05 Thousand USD | -7.79% |
| 2022 Q3 | -145.08 Thousand USD | 19.42% |
| 2022 Q4 | -492.6 Thousand USD | -239.54% |
| 2022 Q1 | -167.04 Thousand USD | -60.84% |
| 2021 Q2 | -72.06 Thousand USD | -44.79% |
| 2021 FY | -336.87 Thousand USD | 56.01% |
| 2021 Q4 | -103.85 Thousand USD | 6.59% |
| 2021 Q3 | -111.18 Thousand USD | -54.29% |
| 2021 Q1 | -49.77 Thousand USD | 38.21% |
| 2020 Q3 | -89.22 Thousand USD | 61.48% |
| 2020 Q2 | -231.61 Thousand USD | 36.45% |
| 2020 FY | -765.84 Thousand USD | 25.93% |
| 2020 Q1 | -364.45 Thousand USD | -46.0% |
| 2020 Q4 | -80.54 Thousand USD | 9.72% |
| 2019 Q2 | -151.34 Thousand USD | 7.49% |
| 2019 FY | -1.03 Million USD | 19.51% |
| 2019 Q4 | -249.63 Thousand USD | 46.81% |
| 2019 Q3 | -469.34 Thousand USD | -210.12% |
| 2019 Q1 | -163.59 Thousand USD | -95.08% |
| 2018 Q4 | -83.86 Thousand USD | 0.0% |
| 2018 FY | -1.28 Million USD | 60.28% |
| 2017 FY | -3.23 Million USD | 0.0% |
| 2010 Q1 | -623.62 Thousand USD | -40693.42% |
| 2010 Q2 | -1.37 Million USD | -120.51% |
| 2009 FY | -1.35 Million USD | 42.63% |
| 2009 Q4 | -1528.73 USD | 0.0% |
| 2009 Q2 | -486.79 Thousand USD | -68.34% |
| 2009 Q1 | -289.17 Thousand USD | 0.0% |
| 2008 FY | -2.35 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -112.522% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | 89.0% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 96.509% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 98.441% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 93.392% |
| Better Therapeutics, Inc. | -38.26 Million USD | 97.264% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 97.512% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 91.253% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 96.906% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 96.958% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 99.035% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | 48.023% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 96.921% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 97.77% |
| Innovation1 Biotech Inc. | -1.36 Million USD | 23.432% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 94.749% |
| Molecular Templates, Inc. | -10.46 Million USD | 89.996% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | 92.549% |
| NexImmune, Inc. | -29.19 Million USD | 96.414% |
| Orgenesis Inc. | -53.63 Million USD | 98.048% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 97.959% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -1241.987% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 93.515% |
| Scopus BioPharma Inc. | -11.71 Million USD | 91.063% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 99.792% |
| Statera Biopharma, Inc. | -98.34 Million USD | 98.935% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | 84.822% |
| Trevena, Inc. | -35.28 Million USD | 97.033% |
| Vaxxinity, Inc. | -58.28 Million USD | 98.204% |
| Vaccinex, Inc. | -22.88 Million USD | 95.425% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 97.935% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 85.585% |